Lidocaine Hydrochloride Monohydrate Чайкафарма (Lidocaine Hydrochloride Monohydrate)

Lidocaine blocks voltage‑gated sodium channels on nerve and cardiac cells, preventing the influx of sodium ions that is essential for depolarisation. This inhibition stops the generation and propagation of action potentials, resulting in loss of sensation in the targeted tissue and stabilisation of abnormal cardiac electrical activity.

The dose of lidocaine is determined by the prescribing clinician based on the specific indication, route of administration, patient weight, age, and clinical condition. Dosage recommendations are provided in the product’s prescribing information and must be tailored to each individual case.

Safety data for lidocaine in pregnancy and lactation are limited. It should only be used when clearly needed and after a risk‑benefit assessment by the healthcare provider. Lidocaine does pass into breast milk in small amounts, so caution is advised for nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and the necessary import documentation.

Lidocaine is an amide‑type local anesthetic with a rapid onset (1–2 minutes) and intermediate duration (1–2 hours). Compared with shorter‑acting agents like procaine, lidocaine provides faster numbness and longer analgesia, while agents such as bupivacaine offer a longer duration but a slower onset. Choice depends on the procedure, required duration, and patient factors.

Lidocaine Hydrochloride Monohydrate should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect it from moisture, direct sunlight, and extreme temperatures. Do not freeze. Inspect the vial for particulate matter before use and discard if the solution is discolored or cloudy.

Lidocaine is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or subcutaneously. The route is selected by the clinician based on the therapeutic goal—local infiltration for anesthesia, intravenous infusion for arrhythmia control, or subcutaneous injection for localized pain relief.

Serious risks include cardiac arrhythmias, severe hypotension, seizures, methemoglobinemia, and life‑threatening allergic reactions such as anaphylaxis. These events are more likely with high plasma concentrations, rapid intravenous bolus, or in patients with pre‑existing cardiac, hepatic, or metabolic disorders.

Lidocaine should be avoided in patients with known hypersensitivity to amide‑type local anesthetics, severe heart block without a pacemaker, significant hepatic impairment, or in those receiving interacting drugs that markedly increase lidocaine levels (e.g., class I antiarrhythmics, amiodarone, cimetidine). Clinical judgment is essential for each case.